CIFoundry
Back to Catalog
Neurology
FDA Cleared

Neurophet AQUA AD Plus

Save to shortlist
Neurophet

Last reviewed Oct 31, 2026 against the sources listed on this page · How we review

At a glance

Neurophet AQUA AD Plus is AI brain MRI analysis software that segments and measures brain regions and atrophy to support evaluation of Alzheimer's disease, including monitoring for ARIA in…

FDA:
510(k) K252496
Epic:
Not on record
Named users:
1 named in public reports
Published study:
Not on record

Description

Neurophet AQUA AD Plus is AI brain MRI analysis software that segments and measures brain regions and atrophy to support evaluation of Alzheimer's disease, including monitoring for ARIA in patients on anti-amyloid therapy. FDA 510(k) K252496, cleared January 2026.

FDA 510(k)MRIbrainneurology

Quick answers

Answered only from the sourced records on this page. Questions we can't answer from the record are left out. How we review

Is Neurophet AQUA AD Plus FDA cleared?
The public FDA database has one record that our team matched to Neurophet AQUA AD Plus. The most recent is 510(k) K252496 (Neurophet AQUA AD Plus), decided Jan 2026. Check that the cleared use matches how you plan to use it.FDA record K252496
Which health systems use Neurophet AQUA AD Plus?
Linked public reports name one organization: Raffles Medical. "Who's using this" below lists them all, plus any the maker reports. Ask the vendor for a reference at an organization like yours.Raffles Medical (Korea Biomedical Review)

Security & contracting

The maker has not reported these details yet. Ask the vendor directly during evaluation.

Workflow stage
Not reported
Integrations
Not reported
Data inputs
Not reported
Deployment
Not reported
Signs a BAA
Not reported
SOC 2 report
Not reported
HITRUST
Not reported
Evidence type
Regulatory submission summary

Readiness details are self-reported by the maker and are not checked by Clinical Intelligence Foundry. Evidence type describes the kind of study or document the listing links to; it is not a rating or endorsement. Confirm compliance documents with the vendor before purchase.

Who's using this

1 organization

Organizations named in public announcements or by the developer. Inclusion is not an endorsement.

Last checked Oct 31, 2026. Spot an error? Let us know through the discussion below.

Get weekly updates for Neurology

Up to 5 new items a week: new tools, FDA decisions and studies. Newest first, never ranked. Confirm by email, unsubscribe any time.

Sources

This listing links to primary sources. Follow the links below to check details directly with the developer, regulator or publication.

Website FDA Record

FDA database records

  • K252496 · 510(k) · Jan 2026
    Neurophet AQUA AD Plus

Matched by our team from the public FDA database; checked Nov 10, 2026.

History (3)Show

Dated events on this listing's public record, newest first.

  1. Sep 27, 2026

    Added to CIFoundry

  2. Jun 30, 2026

    News report names Raffles Medical as a user (Korea Biomedical Review)source

  3. Jan 29, 2026

    FDA 510(k) K252496 decision datesource

Developer

Neurophet

Evaluating this tool?

Get a printable packet for your committee: what the public record shows, the gaps to raise with the vendor, and the questions for this kind of tool.

Prepare evaluation packet

Checklist for your role: Admin · Physician · IT · Compliance

Compare similar tools →

Own this tool?

Claim this listing to update its details and connect with your audience.